{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-24-000021","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.574229+00:00","generated_at":"2026-05-30T03:15:03.294254+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PTC Therapeutics Q3 revenue $196.8M, raises FY2024 guidance to $750-800M, multiple FDA submissions","bullets":["Q3 total revenue $196.8M (vs $196.6M YoY); DMD franchise $124M (Translarna $72M, Emflaza $52M).","Net loss narrowed to $106.7M from $133M; cash & securities $1.01B.","FY2024 revenue guidance raised to $750-800M; GAAP R&D+SG&A $740-835M.","FDA accepted sepiapterin NDA (PKU) with action date July 29, 2025; AADC gene therapy BLA action Nov 13, 2024.","Plans to submit vatiquinone NDA for Friedreich ataxia in Dec 2024; fast track for PTC518 Huntington's."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-24-000021","json":"https://secwatch.observer/filing/0001070081-24-000021.json","markdown":"https://secwatch.observer/filing/0001070081-24-000021.md","text":"https://secwatch.observer/filing/0001070081-24-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008124000021/0001070081-24-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008124000021/tmb-20241107x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:15:03.294254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}